Hi All,
What an amazing week for LBT.
Regarding biom/ copan vs apas:
For me the key differences are
1) the size of labs likely to use full lab automation ie biom/copan type products.
2) apas could be an end to end process. (If including automated streaking and incubation with robotic reading). Others are not yet.
These biom/ copan/ bd fla tla type products are designed to have a large throughput of work and replace a significant percentage of front end lab. They still rely upon a core group of skilled and experience micro staff to report all culture results. This is not an end to end process. These are targeted at the largest labs. BD also have a range of sophisticated full lab automation. Again quite expensive relatively. They are looking at having computer assisted reporting potentially able to report cultures with no growth. No reading of cultures yet.
I would expect the end game for the apas range to cover processing through to reading or reporting. Ie an end to end process with minimal human intervention. There may be some cultures too complex for the a.i to interpret, which would be refered to micro lab staff, but negative cultures and simple single organism cultures may not need any human checking. I would also expect the apas range to be more affordable as well as modular, and therefore target medium to large labs. Perhaps even small labs if price vs efficiency works out.
This is just my opinion on the future direction of micro labs. Could be wrong. But this is where the growth for lbt will be maintained, up to blue sky vision........ Also not factoring in future ai imaging products in development.
Cheers.
Uly
- Forums
- ASX - By Stock
- LBT
- Ann: US FDA Grants Approval for APAS-LBT.AX
Ann: US FDA Grants Approval for APAS-LBT.AX, page-702
-
- There are more pages in this discussion • 597 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
Add LBT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $28.21M |
Open | High | Low | Value | Volume |
1.7¢ | 1.8¢ | 1.7¢ | $24.12K | 1.380M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 114827 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 592184 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 114827 | 0.017 |
1 | 133333 | 0.016 |
4 | 820773 | 0.015 |
4 | 855999 | 0.014 |
6 | 992384 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 592184 | 5 |
0.019 | 748237 | 3 |
0.020 | 799149 | 5 |
0.021 | 600000 | 1 |
0.022 | 705556 | 6 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
LBT (ASX) Chart |